Pharmaceuticals, Biotechnology and Life Sciences
ImmuPharma has met the primary endpoint in additional study, testing Lupuzor, after requests from Investigators and patients involved in the Pivotal Phase III study, permitting patients who participated in the Phase III study, to receive Lupuzor.
ImmuPharma has completed a fundraise totalling £10 million (14.03million) before expenses by placing 6,944,445 new ordinary shares of 10p each…
ImmuPharma has completed a sharing agreement with Lanstead Capital from February 2016, for supporting of ImmuPharma’s pivotal Phase III clinical trial…
ImmuPharma said Friday that 200 patients were recruited and dosed in its Phase III trial of Lupus drug Lupuzor. Furthermore, all 200 patients have passed the 3 months stage, with over 90% of patients (184) have passed 6 months.
ImmuPharma has completed patients recruitment regarding pivotal Phase III clinical trial of Lupuzor, its lead programme for the potential breakthrough…